According to the most recent report by Emergen Research, the global Vulvovaginal Candidiasis (VVC) market size reached USD 971.51 Million in 2021 and is anticipated to grow at a revenue CAGR of 4.2% during the projected period. One of the main factors propelling the market growth for vulvovaginal candidiasis is the increase in vulvovaginal candidiasis infections among women around the world, rising regulatory approvals for the treatment of vulvovaginal candidiasis, and rising number of clinical research studies pertaining to the treatment of vulvovaginal candidiasis.
One of the main causes of vulvovaginal discomfort and discharge is vulvovaginal candidiasis. Inflammation brought on by Candida species defines the disease. Candidal vulvovaginitis accounts for about one-third of cases. According to data from the National Center for Biotechnology Information (NCBI), 70% of women report having experienced candidal vulvovaginitis at some point in their lives, and it accounts for a third of all vulvovaginitis occurrences among reproductive-aged women. 8% of women have recurrent candidal vulvovaginitis. In women with recurrent vaginal candidiasis, several methods, such as oral or topical antifungal therapy, reduce symptomatic clinical recurrences (RVVC).
One of the main factors fueling the expansion of this business is the rise in female vulvovaginal candidiasis prevalence around the globe. Recurrent vulvovaginal candidiasis affects approximately 138 million women annually with a global incidence of 3871 per 100 000 women; 372 million women will have the condition at some point in their lifetime. The highest prevalence (9%) is found in the 25–34 year old age group. As a result, the demand for treatment choices such oral and topical antifungal drugs is increasing among women over the world, which is boosting this industry’s global revenue growth. Even while antifungal drugs, such as topical, can effectively treat the majority of VVC, VVC recurrence is a common problem and can occasionally be quite severe.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/1476
A rise in the number of diabetes patients and an increase in the incidence of antibiotic resistance among people are further factors contributing to the disease’s increased prevalence. Additionally, 15% of these situations are thought to need for unique therapy approaches. Consequently, industry growth is being fueled by the disease’s increased prevalence. The growing need for better therapeutic options is resulting in advancements in R&D, fresh approvals, and drug launches, opening up a lucrative window for industry expansion.
Some Key Highlights From the Report
- In 2021, the retail pharmacy sector had the biggest revenue share. Retail pharmacists assist in the preparation and administration of medications, offer advice to customers on how to fill prescriptions, and warn them about possible drug interactions. Retail pharmacists are available to customers for consultation regarding over-the-counter drugs and other essential healthcare requirements. Retail pharmacists have the ability to fill prescriptions locally, which may be more convenient for patients who prefer a quicker discharge process than completing prescriptions elsewhere. This simplifies the treatment process for the patient and enhances their entire experience. Retail pharmacies facilitate a thorough transformation of the patient’s health care experience, raise patient happiness, and facilitate more qualitative results. These are the main variables influencing the segment’s revenue growth.
- In 2021, Europe contributed significantly to revenue. This is due to an increase in research and development activities, more funding from major corporations, partnerships, a supportive regulatory environment for drugs that treat vulvovaginal candidiasis, enticing government-introduced medical reimbursement policies, and the presence of a strong healthcare infrastructure. These elements significantly accelerated the market’s expansion in this area.
- Mycovia Pharmaceuticals, Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Pfizer, Cadila Pharmaceuticals, SCYNEXIS, Inc., Grupo Ferrer International S.A., Phathom Pharmaceuticals, Inc., and Lupin are a few of the leading companies mentioned in the report on the global vulvovaginal candidiasis market.
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/vulvovaginal-candidiasis-market
Emergen Research has segmented the global vulvovaginal candidiasis market on the basis of drug type, route of administration, distribution channel, and region:
- Drug Type Outlook (Revenue, USD Million; 2019-2030)
- Clotrimazole
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
- Route of Administration Outlook (Revenue, USD Million; 2019-2030)
- Oral
- Topical
- Intravenous
- Distribution Channel Outlook (Revenue, USD Million; 2019-2030)
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Outlook (Revenue, USD Million; 2019-2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Benelux
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Turkey
- Rest of MEA
- North America
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/1476
Explore More Reports Emergen Research:
Endoscopic Closure Systems Market
Automated Blood Collection Market
Multi Cancer Early Detection Market
About Us:
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights
Explore Our Custom Intelligence services | Growth Consulting Services